FDA Approves Lurbinectedin in Combination with Atezolizumab or Atezolizumab and Hyaluronidase-tqjs for Extensive Stage SCLC By Ogkologos - October 16, 2025 7 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the IMforte study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Publishes First Guidance on the Safe Use of Large Language Models in Oncology Practice Study Shows Thymic Health is Linked to Cancer Patients’ Response to Immunotherapy Outcome of EMA Assessment on Use of Lutetium (177Lu) in Treatment of GEP-NETs in Adolescents MOST POPULAR FDA Approves Osimertinib as Adjuvant Therapy for NSCLC with EGFR Exon... January 5, 2021 New reports show staff shortages continue to hold back cancer care June 9, 2022 Metastatic Colorectal Cancer May Spread Early in the Disease, Study Finds July 22, 2019 Pembrolizumab Approved for Some Patients with Advanced Esophageal Cancer August 28, 2019 Load more HOT NEWS Addressing Disparities and Raising Awareness During National Black Family Cancer Awareness... Three Brothers Under The Age Of 6 Are All Fighting The... Sleep Issue Called Hypersomnolence Can Increase The Risk Of Diabetes And... Higher Risk of Invasive Behaviour for Oncogenic Fusions–Driven Paediatric Thyroid Cancers
